BC 7013Alternative Names: BC-7013
Latest Information Update: 04 Mar 2016
At a glance
- Originator Nabriva Therapeutics
- Class Antibacterials
- Mechanism of Action Bacterial protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Clostridium infections